不同分子分型乳腺癌组织中趋化因子 CXCL12 及其受体 CXCR4 和 CXCR7 的表达及临床意义

目的：探讨趋化因子CXCL12及其受体CXCR4和CXCR7在不同分子分型乳腺癌组织中的表达及临床意 义。方法：应用实时定量PCR检查80例不同分子分型乳腺癌组织中的趋化因子CXCL12 mRNA及其受体CXCR4和 CXCR7 mRNA的表达，采用免疫组织化学技术检测160例不同分子分型乳腺癌细胞组织中趋化因子CXCL12蛋白及其 受体CXCR4和CXCR7蛋白的表达，并分析它们在不同分子分型乳腺癌中的表达差异。结果：CXCL12 mRNA及其受 体CXCR4和CXCR7 mRNA在Luminal A和Luminal B型中表达无差异，在HER-2过表达型和三阴性乳腺癌(triple negative breast cancer，TNBC)两个类型之间的表达也无差异，但三者在HER-2过表达型和TNBC中的表达明显高于Luminal A和 Luminal B型(均P<0.05)；CXCL12蛋白、CXCR4蛋白和CXCR7蛋白在HER-2过表达型和TNBC中的阳性表达率均明显高 于Luminal A和Luminal B型(均P<0.05)，但在Luminal A和Luminal B之间及HER-2过表达型和TNBC之间的表达无差异。 结 论：趋化因子CXCL12及其受体CXCR4和CXCR7在HER-2过表达型乳腺癌和TNBC组织中高表达，可能与该类型乳腺 癌预后较差有关，抑制其表达可为该类乳腺癌的治疗提供重要途径。

Expression of chemokine CXCL12 and its receptor (CXCR4#br# and CXCR7) in different molecular subtypes of human#br# breast carcinoma and the clinical significance

Objective: To study the expressions and the clinical signifi cance of chemokine CXCL12 and its receptor CXCR4, CXCR7 in the human breast carcinoma (BC) with diff erent molecular subtypes. Methods: Th e mRNA expressions of CXCL12, CXCR4 and CXCR7 in tissues from 80 patientswith different molecular subtype of BC were measured by qRT-PCR. The protein expressions of CXCL12, CXCR4 and CXCR7 in paraffin-embedded samples from 160 patients with different molecular subtypes were detected by immunohistochemical staining. Results: The mRNA expression levels of CXCL12, CXCR4 and CXCR7 in HER-2 positive BC and TNBC tissues were significantly higher than those in luminal A and luminal B subtype BC tissues (all P<0.05), but their expressions were not different between luminal A and luminal B subtype BC tissues or between HER-2 positive BC and TNBC tissues. The positive expression rates of CXCL12 protein in HER-2 positive BC and TNBC tissues were significantly higher than those in luminal A and luminal B subtype BC tissues (all P<0.05), while their expressions were not different between luminal A and luminal B subtype BC tissues or between HER-2 positive BC and TNBC tissues. Conclusion: High expressions of the gene CXCL12 and its receptor CXCR4 and CXCR7 in HER- 2 positive BC and TNBC may be closely associated with their poor prognosis. Inhibition of their expressions in HER-2 positive BC and TNBC may provide a strategy for treating BC in clinic.